Guggenheim analyst Subbu Nambi raised the firm’s price target on GeneDx (WGS) to $115 from $88 and keeps a Buy rating on the shares. The price target increase reflects the tailwind and upside associated with the American Academy of Pediatrics guideline update, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks